Back Pain News and Research

Latest Back Pain News and Research

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Back pain attitudes questionnaire developed

Researchers have developed a back pain screening tool that assesses the attitudes of patients with back pain, the general population and healthcare professionals.

16 Jun 2014

Back App: A training apparatus for Sitting Disease

Scientific research is increasingly showing strong links between spending too much time sitting and the development of severe long and short term health problems.

12 Jun 2014

New innovative body suit improves horse riders’ balance, symmetry, poor posture

HORSE riders' balance, symmetry and poor posture could be improved thanks to an innovative body suit that works with motion sensors, commonly used by movie makers and the video games industry.

10 Jun 2014

MRI findings rarely associated with spine-related symptoms

Incidental magnetic resonance imaging findings are not generally associated with the development of chronic low back pain or radicular symptoms, US study findings indicate.

5 Jun 2014

Naloxegol holds hope for opioid-induced constipation

Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System.

5 Jun 2014

Article introduces set of proposed standards for research on cLBP

Standardized research methods are needed to make greater progress toward reducing the high burden and costs of chronic low back pain (cLBP), according to a Task Force report in the June 15 issue of Spine.

4 Jun 2014

Researchers investigate correlation between lower back pain and genes

Lower back pain is a broad yet subtle subject. It has widely been associated with early degeneration of the discs of the human spine.

4 Jun 2014

European researchers explore new tools for prevention of back pain

European researchers and clinicians are working hand in hand to unveil the mechanisms leading to back pain, likely the most widespread chronic pathology among humans. Until recently, it was assumed that disc degeneration was the main process behind back pain. The intervertebral discs are joints made of soft and very strain resistant material, placed between the vertebrae of the spine.

4 Jun 2014

InSightec inaugurates first centers in Shanghai

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that the first centers in China offering ExAblate, for non-invasive treatment of uterine fibroids, have opened in Shanghai.

30 May 2014

UNC researchers find new enzyme target for treating chronic pain

Researchers at the UNC School of Medicine have found a new target for treating chronic pain: an enzyme called PIP5K1C.

22 May 2014

New online training module greatly improves medical student clinical skills

An online training module designed for the evaluation and care of chronic pain greatly improved medical student clinical skills, according to a report in the Journal of the American Geriatrics Society.

22 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex, Inc. reports financial results for the three months ended March 31, 2014 and announces LCA-Vision stockholder approval of PhotoMedex's previously announced acquisition of all outstanding shares of LCA-Vision, a leading provider of laser vision correction services under the LasikPlus brand.

12 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

30 Apr 2014

DJOFL first quarter 2014 net sales increase 1.3% to $282.7 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC, for the first quarter ended March 29, 2014.

29 Apr 2014

Methadone safety: New clinical practice guideline from American Pain Society

Improved physician education and patient counseling about methadone safety and ECG monitoring to identify patients at high risk for cardiac problems will lead to safer use of the medication, according to the American Pain Society's Clinical Practice Guideline on Methadone Safety, published this week in The Journal of Pain.

26 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

California Orthopaedic Medical Clinic offers comprehensive surgical solution for spinal stenosis

Like any back surgery, spinal stenosis treatment can be a significant and emotionally taxing moment in a person's life – which is why it is essential to ensure that it is effective the first time by trusting treatment to experts like Dr. Seyed M. Rezaian.

22 Apr 2014